Clinical Trial Update: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study results for the combination of ramucirumab and atezolizumab in non-small cell lung cancer after progression on prior immune checkpoint blockade; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non-small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-08-11